ProteoMediX AG - Product Pipeline Analysis, 2019 Update

Summary

ProteoMediX AG (ProteoMediX) is a medical diagnostic company that identifies and develops novel biomarkers for the early detection of cancer and the personalized treatment. The company develops non-invasive diagnostic tests for the detection, prognosis, stratification, and therapy-selection of prostate cancer. Its biomarkers are discovered using a genetics-guided discovery approach and are used in detecting PI3K/PTEN cancer pathway. ProteoMediX offers proteomics technologies, which are used to analyze glycosylated proteins in prostate tissue and serum from wild-type mice and mice with prostate-specific deletion of the tumor suppressor PTEN. The company serves patients with prostate and other types of cancer. ProteoMediX is headquartered in Schlieren, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company ProteoMediX AG
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
ProteoMediX AG Company Overview
ProteoMediX AG Company Snapshot
ProteoMediX AG Pipeline Products and Ongoing Clinical Trials Overview
ProteoMediX AG Pipeline Analysis Overview
ProteoMediX AG - Key Facts
ProteoMediX AG - Major Products and Services
ProteoMediX AG Pipeline Products by Development Stage
ProteoMediX AG Pipeline Products Overview
Diagnostic Test - Prostate Cancer
Diagnostic Test - Prostate Cancer Product Overview
Prostate Cancer Prognosis Assay
Prostate Cancer Prognosis Assay Product Overview
Prostate Cancer Stratification Assay
Prostate Cancer Stratification Assay Product Overview
ProteoMediX Prostate Cancer Test
ProteoMediX Prostate Cancer Test Product Overview
ProteoMediX AG - Key Competitors
ProteoMediX AG - Key Employees
ProteoMediX AG - Locations And Subsidiaries
Head Office
Recent Developments
ProteoMediX AG, Recent Developments
Sep 11, 2018: New publication confirms that the use of ProteoMediX proprietary blood-based biomarkers improves clinically significant prostate cancer diagnosis
Apr 13, 2018: Novel Biomarker Test Avoids Biopsies by Accurately Predicting High-Grade Prostate Cancer
Jun 21, 2017: Dr. Helge Lubenow elected as a new member to the Board of Directors
Mar 27, 2017: Recent Clinical Study Results of ProteoMediX Prostate Cancer Test Presented at the 2017 Annual European Association of Urology Congress
Jan 13, 2017: ProteoMediX receives ISO 13485:2012 Certification
Sep 08, 2014: CTI supports the development of a prostate cancer risk stratification test
Jun 17, 2014: Harry Welten joins the Board of Directors of ProteoMediX
May 19, 2014: ProteoMediX adds Mark Emberton as new clinical advisor
Apr 26, 2013: ProteoMediX Announces Publication of Results of its Biomarkers
Jul 21, 2011: New Publication Proofs Prognostic Potential Of ProteoMediX Proprietary Biomarkers
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

List of Tables
ProteoMediX AG Pipeline Products and Ongoing Clinical Trials Overview
ProteoMediX AG Pipeline Products by Equipment Type
ProteoMediX AG Pipeline Products by Indication
ProteoMediX AG, Key Facts
ProteoMediX AG, Major Products and Services
ProteoMediX AG Number of Pipeline Products by Development Stage
ProteoMediX AG Pipeline Products Summary by Development Stage
Diagnostic Test - Prostate Cancer - Product Status
Diagnostic Test - Prostate Cancer - Product Description
Prostate Cancer Prognosis Assay - Product Status
Prostate Cancer Prognosis Assay - Product Description
Prostate Cancer Stratification Assay - Product Status
Prostate Cancer Stratification Assay - Product Description
ProteoMediX Prostate Cancer Test - Product Status
ProteoMediX Prostate Cancer Test - Product Description
ProteoMediX AG, Key Employees
Glossary

List Of Figures

List of Figures
ProteoMediX AG Pipeline Products by Equipment Type
ProteoMediX AG Pipeline Products by Development Stage

ProteoMediX AG - Product Pipeline Analysis, 2019 Update

ProteoMediX AG (ProteoMediX) is a medical diagnostic company that identifies and develops novel biomarkers for the early detection of cancer and the personalized treatment. The company develops non-invasive diagnostic tests

USD 750 View Report

ProteoMediX AG - Product Pipeline Analysis, 2018 Update

ProteoMediX AG (ProteoMediX) is a medical diagnostic company that identifies and develops novel biomarkers for the early detection of cancer and the personalized treatment. The company develops non-invasive diagnostic tests

USD 750 View Report

Ed. Zublin AG - Strategy, SWOT and Corporate Finance Report

Ed. Zublin AG - Strategy, SWOT and Corporate Finance ReportEd. Zublin AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Allreal Holding AG - Strategy, SWOT and Corporate Finance Report

Allreal Holding AG - Strategy, SWOT and Corporate Finance ReportAllreal Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available